Answers are grounded in this paper and cite their sources.
Up to 30% of patients with breast cancer relapse after primary treatment. There are no sensitive and reliable tests to monitor these patients and detect distant metastases before overt recurrence. Here, we demonstrate the use of personalized circulating tumor DNA (ctDNA) profiling for detection of recurrence in breast cancer.
No takes yet. Share an insight, caveat, or question.
Coombes et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: